The therapeutic standard of care for Alzheimer’s has not changed for over 12 years and currently there are effectively only 4 therapies approved for treatment of Alzheimer’s disease. These only treat the cognitive symptoms, do not modify disease progression and at best they are only modestly active, gradually losing their efficacy as the disease becomes more severe. Cognition Therapeutics has applied its innovative drug discovery platform and discovered first in-class small molecule inhibitors of Abeta oligomer binding to neurons that have the potential to modify disease progression in Alzheimer’s disease.

Not only do these drug candidates restore functional competence to neuronal and synaptic processes but also they revive cognitive function in animal models of Abeta-induced cognitive impairment. Since Cognition Therapeutics’ drug discovery platform is optimized for combined drug target and candidate ligand discovery in neurotoxic proteinopathies it can be configured to model a number of other neurodegenerative disorders involving abnormal neuronal protein folding and aggregation. These include Parkinson’s, Lou Gehrig’s and Creutzfeldt-Jakob diseases, each of which represent areas of high unmet medical need.